Clara Ferreira1, David Sterling2, Margaret Reynolds2, Kathryn Dusenbery2, Clark Chen3, Parham Alaei2. 1. Department of Radiation Oncology, University of Minnesota, Minneapolis, MN. Electronic address: cferreir@umn.edu. 2. Department of Radiation Oncology, University of Minnesota, Minneapolis, MN. 3. Department of Neurosurgery, University of Minnesota, Minneapolis, MN.
Abstract
PURPOSE: GammaTile cesium-131 (131Cs) permanent brain implant has received Food and Drug Administration (FDA) clearance as a promising treatment for certain brain tumors. Our center was the first institution in the United States after FDA clearance to offer the clinical use of GammaTile brachytherapy outside of a clinical trial. The purpose of this work is to aid the medical physicist and radiation oncologist in implementing this collagen carrier tile brachytherapy (CTBT) program in their practice. METHODS: A total of 23 patients have been treated with GammaTile to date at our center. Treatment planning system (TPS) commissioning was performed by configuring the parameters for the 131Cs (IsoRay Model CS-1, Rev2) source, and doses were validated with the consensus data from the American Association of Physicists in Medicine TG-43U1S2. Implant procedures, dosimetry, postimplant planning, and target delineations were established based on our clinical experience. Radiation safety aspects were evaluated based on exposure rate measurements of implanted patients, as well as body and ring badge measurements. RESULTS: An estimated timeframe of the GammaTile clinical responsibilities for the medical physicist, radiation oncologist, and neurosurgeon is presented. TPS doses were validated with published dose to water for 131Cs. Clinical aspects, including estimation of the number of tiles, treatment planning, dosimetry, and radiation safety considerations, are presented. CONCLUSION: The implementation of the GammaTile program requires collaboration from multiple specialties, including medical physics, radiation oncology, and neurosurgery. This manuscript provides a roadmap for the implementation of this therapy.
PURPOSE:GammaTilecesium-131 (131Cs) permanent brain implant has received Food and Drug Administration (FDA) clearance as a promising treatment for certain brain tumors. Our center was the first institution in the United States after FDA clearance to offer the clinical use of GammaTile brachytherapy outside of a clinical trial. The purpose of this work is to aid the medical physicist and radiation oncologist in implementing this collagen carrier tile brachytherapy (CTBT) program in their practice. METHODS: A total of 23 patients have been treated with GammaTile to date at our center. Treatment planning system (TPS) commissioning was performed by configuring the parameters for the 131Cs (IsoRay Model CS-1, Rev2) source, and doses were validated with the consensus data from the American Association of Physicists in Medicine TG-43U1S2. Implant procedures, dosimetry, postimplant planning, and target delineations were established based on our clinical experience. Radiation safety aspects were evaluated based on exposure rate measurements of implanted patients, as well as body and ring badge measurements. RESULTS: An estimated timeframe of the GammaTile clinical responsibilities for the medical physicist, radiation oncologist, and neurosurgeon is presented. TPS doses were validated with published dose to water for 131Cs. Clinical aspects, including estimation of the number of tiles, treatment planning, dosimetry, and radiation safety considerations, are presented. CONCLUSION: The implementation of the GammaTile program requires collaboration from multiple specialties, including medical physics, radiation oncology, and neurosurgery. This manuscript provides a roadmap for the implementation of this therapy.
Authors: Paolo Palmisciano; Ali S Haider; Kishore Balasubramanian; Randy S D'Amico; Alla Gabriella Wernicke Journal: J Neurooncol Date: 2022-06-13 Impact factor: 4.506
Authors: Dilini S Pinnaduwage; Shiv P Srivastava; Xiangsheng Yan; Shyam Jani; David G Brachman; Stephen P Sorensen Journal: Technol Cancer Res Treat Date: 2022 Jan-Dec
Authors: Dominic J Gessler; Elizabeth C Neil; Rena Shah; Joseph Levine; James Shanks; Christopher Wilke; Margaret Reynolds; Shunqing Zhang; Can Özütemiz; Mehmet Gencturk; Mark Folkertsma; W Robert Bell; Liam Chen; Clara Ferreira; Kathryn Dusenbery; Clark C Chen Journal: Neurooncol Adv Date: 2021-12-27
Authors: Theodore Arsenault; Collin M Labak; Kevin Chaung; Raymond F Muzic; Arash Kardan; Andrew Sloan; Serah Choi; Tarun Podder; Zi Ouyang Journal: Cureus Date: 2021-11-03
Authors: Shahil Mehta; April K Vassantachart; Croix C Fossum; Wensha Yang; Zhilei L Shen; Ki-Eun Chang; Jason C Ye; Thomas C Chen; Eric L Chang Journal: Cureus Date: 2021-11-14
Authors: Teresa P Easwaran; David Sterling; Clara Ferreira; Lindsey Sloan; Christopher Wilke; Elizabeth Neil; Rena Shah; Clark C Chen; Kathryn E Dusenbery Journal: Cureus Date: 2021-11-12